Understanding Barriers to Diagnosis in a Rare, Genetic Disease: Delays and Errors in Diagnosing Schwannomatosis - Merker, Vanessa L.; Slobogean, Bronwyn; Jordan, Justin T.; Langmead, Shannon; Meterko, Mark; Charns, Martin P.; Elwy, A. Rani; Blakeley, Jaishri O.; Plotkin, Scott R. (medRxiv, 2022)
Diagnosis of rare, genetic diseases is challenging, but conceptual frameworks of the diagnostic process can be used to guide benchmarking and process improvement initiatives. Using the National Academy of Medicine diagnostic framework, we assessed the extent of, and reasons for diagnostic delays and diagnostic errors in schwannomatosis, a neurogenetic syndrome characterized by nerve sheath tumors and chronic pain. We reviewed the medical records of 97 people with confirmed or probable schwannomatosis seen in two U.S. tertiary care clinics. Time-to-event analysis revealed a median time from first symptom to diagnosis of 16.7 years (95% CI, 7.5-26.0 years) and median time from first medical consultation to diagnosis of 9.8 years (95% CI, 3.5-16.2 years). Factors associated with longer times to diagnosis included initial signs/symptoms that were intermittent, non-specific, or occurred at younger ages (p<0.05). Thirty-six percent of patients experienced a misdiagnosis of their underlying genetic condition (18.6%), pain etiology (16.5%) and/or tumor classification (11.3%). One-fifth (19.6%) of patients had a clear missed opportunity for genetics workup that could have led to an earlier schwannomatosis diagnosis. These results suggest that interventions in clinician education, genetic testing availability, expert review of pathology findings, and automatic triggers for genetics referrals may improve diagnosis of schwannomatosis.Competing Interest StatementVanessa Merker reports consulting income from the Neurofibromatosis Network. Justin Jordan reports consulting income from Navio Theragnostics, CereXis, Recursion, Health2047; <1% stock ownership in Navio Theragnostics; Royalties from Elsevier. Jaishri Blakeley has served as a paid consultant for Astella Pharma, Abbvie, TriAct/BiPar Sciences and has had research support from GlaxoSmithKlein, Bristol Meyer Squibb, and AstraZeneca. Scott Plotkin is co-founder of NFlection Therapeutics and NF2 Therapeutics; serves on the Scientific Advisory Board and has stock in SonALAsense; and consults for Akouos.Funding StatementThis study was funded by Childrens Tumor Foundation Young Investigator Award 2015-01-005 and the Program in Cancer Outcomes Research Training (National Cancer Institute R25CA92203).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards at Mass General Brigham, Johns Hopkins Medicine, and Boston University Medical Center gave ethical approval for this work. A waiver of informed consent was granted for this retrospective medical record review.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.